Research & Publications

Recent publications on liquid biopsy

No.Publication details
1The liver niche accelerates, while the lung niche restrains secondary spread of breast cancer
Sznurkowska MK, Castro-Giner F, D’Anna I, Krol I, Zhang Y, Ozimski LL, Saini M, Zhou J, Asawa S, Gremmelspacher D, Ring A, Strittmatter K, Schwab FD, Zhang YW, Budinjas S, Vujanovic M, Kontarakis Z, Pontecorvi G, Albrecht F, Mertz KD, Auray G, Giachino C, Taylor V, Gvozdenovic A, Kovacs WJ, Malanchi I, Frauchiger-Heuer H, Wicki A, Vetter M, Ligorio M, Aceto N. Cancer Discov. 2026 Sep 22. doi: 10.1158/2159-8290.CD-25-1652. Epub ahead of print. PMID: 42770697.
2Ki-67 promotes circulating tumor cell intravasation and metastasis in breast cancer
Zhang Y, Zhou J, Strittmatter K, Zhang YW, Waldmeier M, Asawa S, Vujanovic M, Budinjas S, Saini M, Ildiz ES, Gvozdenovic A, Kovacs W, Castro-Giner F, Aceto N. Cell Rep. 2026 May 26;45(5):117354. doi: 10.1016/j.celrep.2026.117354. Epub 2026 May 15. PMID: 42139058.
3Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies
Oner E, M Saini V, Cahill C, O’Toole H, Li JW, Gately K, Anagnostou V. Front Oncol. 2026 Aug 10;16:1806868. doi: 10.3389/fonc.2026.1806868. PMID: 42639369; PMCID: PMC13501364.
4Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers
Landon BV, Huang J, Evangelopoulou EG, Anagnostou V, Canzoniero JV. Int Rev Cell Mol Biol. 2026;399:113-143. doi: 10.1016/bs.ircmb.2024.12.002. Epub 2024 Dec 14. PMID: 41720562.
5Liquid biopsies across the cancer care continuum
Landon BV, Annapragada AV, Niknafs N, Velculescu VE, Anagnostou V. Nat Med. 2025 Dec;31(12):4006-4021. doi: 10.1038/s41591-025-04093-9. Epub 2025 Dec 10. PMID: 41372534; PMCID: PMC13429241.
6Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast Cancer
Woo HJ, Rademacher PN, Shin HY, Lee J, Intisar A, Warkiani ME, Joung JY, Rzhevskiy A, Coith C, Harten F, Hilpert F, Schmalfeldt B, Riethdorf S, Pantel K, Joosse SA, Kim MS. Anal Chem. 2025 Aug 19;97(32):17452-17461. doi: 10.1021/acs.analchem.5c02154. Epub 2025 Jul 14. PMID: 40658815.
7International expert consensus on the clinical integration of circulating tumor cells in solid tumors
Nicolò E, Reduzzi C, Pierga JY, Gazzaniga P, Stoecklein NH, Denninghoff V, Rothwell DG, De Bono JS, Marchetti D, Lianidou E, Riethdorf S, Generali D, Hofman P, Gerratana L, Kuhn P, Thiery JP, Ignatiadis M, Bidard FC, Lucci A, Kasimir-Bauer S, Serrano MJ, Cristofanilli M. Eur J Cancer. 2025 Dec 9;231:116050. doi: 10.1016/j.ejca.2025.116050. Epub 2025 Oct 20. Erratum in: Eur J Cancer. 2026 Jan 17;233:116167. doi: 10.1016/j.ejca.2025.116167. PMID: 41172567.
8Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS)
Pantel K, Alix-Panabières C, Hofman P, Stoecklein NH, Lu YJ, Lianidou E, Giacomini P, Koch C, de Jager V, Deans ZC, Fairley J, Patton SJ, Toledo RA, Schuuring E, Heitzer E, Hendrix A, Ricklefs FL, Thakur BK, von Bubnoff N, Pierga JY, Gebhardt C, Andersen CL, Fijneman R, Malats N, Hallermayr A, Chelala C, Joosse SA, Ciliberto G. J Exp Clin Cancer Res. 2025 May 23;44(1):156. doi: 10.1186/s13046-025-03398-4. PMID: 40410806; PMCID: PMC12100835.
9Clinical Validity of Repeated Circulating Tumor Cell Enumeration as an Early Treatment Monitoring Tool for Metastatic Breast Cancer in the PREDICT Global Pooled Analysis
Janni W, Friedl TWP, Yab TC, Bidard FC, Cristofanilli M, Hayes DF, Ignatiadis M, Regan MM, Alix-Panabieres C, Barlow WE, Caldas C, Carey LA, Dirix L, Fehm T, Garcia-Saenz JA, Gazzaniga P, Generali D, Gerratana L, Gisbert-Criado R, Jacot W, Jiang Z, Joosse SA, Lianidou E, López López R, Magbanua MJM, Manso L, Mavroudis D, Müller V, Munzone E, Pantel K, Pierga JY, Rack B, Riethdorf S, Rugo HS, Sideras K, Sleijfer S, Smerage J, Stebbing J, Terstappen LWMM, Vidal-Martínez J, Wallwiener M, Giridhar KV, Liu MC. Clin Cancer Res. 2025 Jun 3;31(11):2196-2209. doi: 10.1158/1078-0432.CCR-24-3108. PMID: 40100138; PMCID: PMC12130808.
10HER2 phenotyping of CTCs in breast cancer: a comparison across the spectrum of tissue HER2 expression level
Molteni E, Foffano L, Pontolillo L, Nicolò E, Pastò B, Guimaraes G, Bayou N, Serafini MS, Gianni C, D’Amico P, Andreopoulou E, Davis AA, Gradishar WJ, Puglisi F, Cristofanilli M, Gerratana L, Reduzzi C. J Liq Biopsy. 2026 Sep 30;14:100667. doi: 10.1016/j.jlb.2026.100667. PMID: 42890328; PMCID: PMC13671332.
11The Landscape of Tumor Dissemination in Leptomeningeal Disease: Mapping CTC Plasticity and Regional Heterogeneity Across Blood and CSF Compartments
Shishido SN, Chaudhuri B, Mushran V, Ihle K, Wang Y, Egelston CA, Hicks J, Feldman L, Barragan E, Kuhn P. Cancers (Basel). 2026 Sep 26;18(19):3124. doi: 10.3390/cancers18193124. PMID: 42882819.

Recent publications on liquid biopsy from HSLB members

No.Publication details
1ESR1 methylation and ESR1 mutations in circulating tumor cells (CTCs) and paired plasma-cfDNA of advanced breast cancer patients: A feasibility proof-of-concept study
Stergiopoulou D, Markou A, Nicolo E, Serafini MS, Zhang Q, Zhang Y, Gerratana L, Davis AA, Liu H, Gradishar WJ, Reduzzi C, Cristofanilli M, Lianidou E. Mol Oncol. 2026 Aug;20(8):2102-2113. doi: 10.1002/1878-0261.70254. Epub 2026 May 27. PMID: 42201922; PMCID: PMC13398972.
2Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients
Werner S, Tennstedt P, Pose RC, Müller C, Besler K, Schneegans S, Alawi M, Roesch MC, Peine S, Bonci D, Budna-Tukan J, Lianidou E, Alix-Panabières C, Tilki D, Pantel K. Mol Oncol. 2026 Mar 26:10.1002/1878-0261.70244. doi: 10.1002/1878-0261.70244. Epub ahead of print. PMID: 41885368; PMCID: PMC13398947.
3Metabolic marker profiling of circulating tumour cells in NSCLC patients treated with osimertinib: focus on MCT1 and MCT4
Mangani K, Pantazaka E, Lianidou E, Georgoulias V, Kotsakis A, Markou A, Kallergi G. Ther Adv Med Oncol. 2026 Feb 15;18:17588359261416422. doi: 10.1177/17588359261416422. PMID: 41705139; PMCID: PMC12907484.
4The phenotypic heterogeneity of tumor-derived cells in the bloodstream of pancreatic cancer patients
Tagari C, Mangani K, Gogolides M, Roumeliotou A, Golegou P, Xagara A, Koinis F, Frisan T, Pateras IS, Karagiannis SN, Kotsakis A, Kallergi G. Front Cell Dev Biol. 2026 Sep 14;14:1881239. doi: 10.3389/fcell.2026.1881239. PMID: 42807419; PMCID: PMC13617025.
5The Impact of Combretastatin A-4 on Cancer Cells and Circulating Tumor Cells (CTCs): A Multi-Assay Approach
Papakonstantinou D, Vardas V, Varouhaki DM, Kotzamouratoglou A, Mangani K, Ju JA, Alix-Panabières C, Martin SS, Athanassopoulos CM, Kallergi G. Oncol Res. 2026 Sep 14;34(10):1. doi: 10.32604/or.2026.085665. PMID: 42769799; PMCID: PMC13591330.
6Integrative analysis of circulating tumor cells (CTCs) and exosomes from small-cell lung cancer (SCLC) patients: a comprehensive approach
Papakonstantinou D, Roumeliotou A, Pantazaka E, Shaukat AN, Christopoulou A, Koutras A, Dimitrakopoulos FI, Georgoulias V, Xagara A, Chantzara E, Koinis F, Kotsakis A, Stathopoulos C, Kallergi G. Mol Oncol. 2025 Jul;19(7):2038-2055. doi: 10.1002/1878-0261.13765. Epub 2024 Nov 22. PMID: 39575761; PMCID: PMC12234381.
7Detection rate for ESR1 mutations is higher in circulating-tumor-cell-derived genomic DNA than in paired plasma cell-free DNA samples as revealed by ddPCR
Smilkou S, Ntzifa A, Tserpeli V, Balgkouranidou I, Papatheodoridi A, Razis E, Linardou H, Papadimitriou C, Psyrri A, Zagouri F, Kakolyris S, Lianidou E. Mol Oncol. 2025 Jul;19(7):2109-2119. doi: 10.1002/1878-0261.13787. Epub 2025 Jan 4. PMID: 39754401; PMCID: PMC12234389.
8Development and Broad Application of a Double Drop-Off ddPCR Assay for Simultaneous Detection of Four FGFR3 Mutations in Tissue and Liquid Biopsy Samples
Thanou E, Gavalas N, Kabrani E, Grigoriou F, Konstantinou A, Malamatini V, Chourdaki Peristeri C, Lianidou E, Bamias A, Markou A. Cancers (Basel). 2026 Aug 14;18(16):2634. doi: 10.3390/cancers18162634. PMID: 42649945; PMCID: PMC13510398.
9AXL-mRNA Overexpression in Size-Based Enriched Circulating Tumor Cells as a Potential Biomarker for Anti-AXL Targeted Therapies in Non-Small-Cell Lung Cancer
Ntzifa A, Themistokli E, Strati A, Zavridou M, Tsaroucha E, Sfika A, Psyrri A, Balgouranidou I, Kotsakis A, Georgoulias V, Lianidou E. Cancers (Basel). 2026 May 28;18(11):1759. doi: 10.3390/cancers18111759. PMID: 42279342; PMCID: PMC13256021.
10Analytical and clinical validation of a novel CE-IVD kit for PIK3CA hotspot mutations in liquid biopsy samples
Stergiopoulou D, Smilkou S, Tzanikou E, Kaklamanis L, Georgoulias V, Koukli I, Markou A, Lianidou E. J Liq Biopsy. 2026 Feb 18;11:100458. doi: 10.1016/j.jlb.2026.100458. PMID: 41756001; PMCID: PMC12933448.
11Epigenetics and CTCs: New biomarkers and impact on tumor biology
Ntzifa A, Lianidou E. Int Rev Cell Mol Biol. 2025;392:177-198. doi: 10.1016/bs.ircmb.2024.03.002. Epub 2024 Jun 1. PMID: 40287220.